Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor…
Read More...
Read More...